What's expected at EHA 2028?

0 Phase 3 trials are estimated to complete within the conference window. Focus areas: Hematology — heme-onc + benign hem.

How is this list generated?

Phase 3 trials with primary completion dates in the 4 months leading up to + 1 month after the conference, sourced from ClinicalTrials.gov. Not every trial will present at the conference — but most pivotal data in the area typically debuts within this window.

EHA 2028 — European Hematology Association Annual Congress

European hem-onc + benign hematology counterpart to ASH. Key venue for European-led CAR-T, bispecific, and BTK inhibitor data.

Month 6, 2028 Various (Madrid, Frankfurt, Vienna) Hematology — heme-onc + benign hem Upcoming

Phase 3 watch list (0 trials in the ±2-month window)

Trials with primary completion in the months leading up to + just after the conference — the typical window for pivotal data presentations.

No Phase 3 trials with completion in this window.

Recent / nearby approvals in the area

No nearby approvals in the area.

Subscribe to conference alerts

Get every Phase 3 readout + approval in this therapeutic area:

Phase 3 readouts RSS
Recent approvals RSS
Build a custom filter

All EHA years + other conferences
Full Phase 3 readout calendar
Upcoming PDUFA dates
CI briefs

EHA 2028 — European Hematology Association Annual Congress

Phase 3 watch list (0 trials in the ±2-month window)

Recent / nearby approvals in the area

Subscribe to conference alerts

Related